BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Sionna Therapeutics discontinued SION-719 as an add on to Trikafta after its Phase 2a trial showed a placebo adjusted sweat chloride change of minus 1.0 mmol/L (p=0.7). Market reports put the one day share decline at roughly 92 percent.
Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan missed its primary endpoint in PH-HFpEF, with a 3.5 meter walk distance difference versus placebo (p=0.63). The company plans a Type C meeting with the FDA.
Silence Therapeutics' divesiran hit its primary endpoint in polycythemia vera, with an 88 percent response rate versus 19 percent for placebo (p<0.0001) in the Phase 2 SANRECO trial. Phase 3 is planned for the first half of 2027.
Takeda and Protagonist's rusfertide, the rival hepcidin therapy in the same disease, has an FDA decision due this quarter under priority review.
Grail's Galleri test goes before an FDA advisory panel on September 23, the first multi cancer early detection test to reach a panel with a completed premarket approval application.
BioSpace reported BMS's Cobenfy is struggling to gain commercial traction in schizophrenia as MapLight advances a rival muscarinic program.
⚡ Executive Takeaway
In yesterday morning's edition we wrote that capital is moving from pipeline to plumbing. By the closing bell, the market had demonstrated why. Sionna Therapeutics looked like the textbook of a de risked biotech: a clinical stage company in a validated field, aimed at what that field considers the root defect in cystic fibrosis, holding more than a quarter billion dollars in cash. One 15 patient crossover readout erased roughly nine tenths of its equity value in an afternoon. Tenax lost a Phase 3 the same day. Silence won a Phase 2 the same day. Three readouts, three violent repricings, one session.
The transferable point is that in drug development risk does not amortize as a company matures. It concentrates into readout days. The de risked label describes stage, not risk, because a single asset thesis stays binary no matter how late it gets. That distinction is what the infrastructure buyers we covered yesterday are paying to escape, and it looks more rational every time the market has a session like that one. We close that loop Friday. 👉 Read Full Analysis
🧬 Clinical Readouts
The most watched outside challenge to Vertex's cystic fibrosis franchise ended in one afternoon. SION | VRTX
Sionna Therapeutics reported that SION-719, its NBD1 stabilizer, produced no meaningful sweat chloride reduction as an add on to Trikafta, with a placebo adjusted change of minus 1.0 mmol/L (p=0.7) in the 15 patient PreciSION CF crossover trial. The company discontinued the add on program and will prioritize its SION-451 plus SION-2222 dual combination, which cleared a 120 subject Phase 1. Market reports put the one day share decline at roughly 92 percent, against $268.3 million in quarter end cash. The central question, whether stabilizing NBD1 adds benefit on top of triple therapy, remains unanswered in patients.
Oral levosimendan missed its Phase 3, and the subgroups will keep the argument alive. TENX
Tenax Therapeutics' LEVEL trial in pulmonary hypertension with heart failure with preserved ejection fraction showed a 3.5 meter difference on six minute walk distance (p=0.63) across 241 randomized patients, and the key symptom score was flat. Prespecified subgroups of sicker and older patients improved by more than 26 meters, and NT-proBNP fell 49 percent versus placebo. Tenax will take a population enrichment strategy to a Type C meeting with the FDA. Subgroup wins inside a failed trial generate hypotheses, not approvals, and regulators will want the enriched population tested prospectively.
🩸 RNA Therapeutics
RNA interference just posted the strongest randomized data yet in polycythemia vera. SLN | TAK
Silence Therapeutics' divesiran, an siRNA that raises the body's own hepcidin to curb red blood cell overproduction, delivered an 88 percent response rate versus 19 percent for placebo (p<0.0001) in the 48 patient SANRECO trial, cutting phlebotomies from 2.1 per patient to 0.2 with dosing as infrequent as every 12 weeks. Phase 3 is planned for the first half of 2027. The tension is timing: Takeda and Protagonist's rusfertide, a hepcidin mimetic peptide built on the same biology, is under FDA priority review with a decision due this quarter, which would give it years of head start in the market divesiran wants.
🔬 Diagnostics
The first multi cancer blood test gets its day before an FDA panel on September 23. GRAL
The FDA's Molecular and Clinical Genetics Panel will review Grail's premarket approval application for the Galleri test on September 23, resting on PATHFINDER 2 data from 25,490 participants with a year of follow up plus more than 70,000 participants from the NHS-Galleri screening round in the United Kingdom. Galleri reads methylation patterns in blood to flag cancers before symptoms and predict where they started. A multi cancer early detection test has never been through a PMA panel before, so the evidence bar this meeting sets becomes the template for the whole category.
📋 Quick Hits
Radiopharma's precision promise is running into toxicity problems in the clinic, per STAT reporting, a caveat worth holding against the sector's infrastructure moment.
Biogen's targeted ALS therapy is reversing decline in some patients, per a BioSpace feature on the program's expanding evidence.
Psychedelics are approaching a market breakthrough as clinical and policy support build, BioSpace reports.
Five biotech IPOs remain queued to price this week, the running test of whether the reopened window holds through August.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full PreciSION CF and LEVEL data tables, including the prespecified subgroup results
The divesiran versus rusfertide head to head comparison in polycythemia vera
The Galleri PMA timeline and what the September 23 panel will actually weigh
A 14 question FAQ across all four stories
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The checklist for spotting binary risk hiding inside a de risked story, and the one question Sionna's holders needed to ask before yesterday
💊 How the polycythemia vera market splits between a peptide with a decision this quarter and an siRNA dosed four times a year
📊 What Grail's September 23 panel decides for everyone building blood based cancer screening, before a single vote is cast
🎯 Plus the catalysts to watch into Friday's full calendar
Two binary blowups and one clean win in a single session is the sharpest illustration yet of why last week's biggest checks went to plumbing instead of pipeline. We pull that thread through Friday. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →